van den Hof S, Beaumont M T A, Berbers G A M, de Melker H E
Centre for Infectious Disease Epidemiology, National Institute of Public Health and the Environment, Bilthoven, The Netherlands.
Epidemiol Infect. 2003 Aug;131(1):703-9. doi: 10.1017/s0950268803008641.
To obtain insight into mumps immunity 9 years after introduction of vaccination in The Netherlands, antibodies were measured in a national sample (n = 8298) and in clustered religious groups with low vaccine acceptance (n = 254). All sera were tested by indirect ELISA, and agreement with neutralization assay was assessed in a subsample (n = 623). Overall seroprevalence in the adult age groups in the national sample was 96.2% (95% confidence interval 95.4-97.0%). Seroprevalence was somewhat lower in the vaccinated age groups, but still sufficient to maintain herd immunity. After the first dose of vaccine, an increase up to age three years to 93.2% (89.8-96.6%) and a subsequent decline in prevalence to 88.9% (81.7-96.0%) at age 7 years was seen. Seroprevalence in those eligible for two vaccinations was 94.4% (91.3-97.4%). In the religious groups, seroprevalence was generally lower in the age group 1-4 years (30% (18-95%)) than in the national sample, but similar in the older age groups. Seroprevalence as estimated by neutralization assay was only slightly lower for all age groups > or = 1 year. Therefore, the indirect ELISA is a reliable method for measuring mumps virus-specific antibodies in population-based studies. However, to allow for inter-laboratory comparison, international unitage should be developed.
为深入了解荷兰引入腮腺炎疫苗9年后的腮腺炎免疫情况,在一个全国性样本(n = 8298)和疫苗接种率低的聚集性宗教群体(n = 254)中检测了抗体。所有血清均通过间接ELISA检测,并在一个子样本(n = 623)中评估了与中和试验的一致性。全国性样本中成年年龄组的总体血清阳性率为96.2%(95%置信区间95.4 - 97.0%)。接种疫苗年龄组的血清阳性率略低,但仍足以维持群体免疫。接种第一剂疫苗后,3岁时血清阳性率升至93.2%(89.8 - 96.6%),随后7岁时患病率降至88.9%(81.7 - 96.0%)。 eligible for two vaccinations是指符合接种两剂疫苗条件的,这里翻译为“符合接种两剂疫苗条件的人群的血清阳性率为94.4%(91.3 - 97.4%)”。在宗教群体中,1 - 4岁年龄组的血清阳性率通常低于全国性样本(30%(18 - 95%)),但在年龄较大的组中相似。通过中和试验估计的所有≥1岁年龄组的血清阳性率仅略低。因此,间接ELISA是在基于人群的研究中测量腮腺炎病毒特异性抗体的可靠方法。然而,为了便于实验室间比较,应制定国际单位标准。